Treatments for Plaque Psoriasis

Plaque Psoriasis: Biologic Therapy Toxicity Profiles
January 17, 2022

A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.

Bimekizumab’s Potential in Moderate-to-Severe Plaque Psoriasis
January 17, 2022

A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.

Moderate to Severe Plaque Psoriasis: An Overview of Biologic Agents
January 10, 2022

A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.

Moderate to Severe Plaque Psoriasis: What is the Standard of Care?
January 10, 2022

Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.

Plaque Psoriasis Case 1: Selecting a Therapeutic Class
January 05, 2022

The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.

Plaque Psoriasis Case 1: Patient Counseling and Approaching Therapy
January 05, 2022

Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.

Understanding the Psychosocial Burden of Plaque Psoriasis
December 23, 2021

Considerations for the psychological and social impact that plaque psoriasis may have on a patient.

Challenges in Diagnosing Plaque Psoriasis
December 23, 2021

Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis

Study: Risk of Psoriasis Related to BMI
December 21, 2021

A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.

Apremilast Use During COVID-19
December 21, 2021

A recent study investigated apremilast use for psoriasis during COVID-19 infection.